Menu
A recent survey of biotechnology firms reported that Trump's planned pharmaceutical tariffs would set back scientific innovation and reduce patients' access to medications.

As Trump Pharmaceutical Tariffs Loom, Drug Industry Pledges Investment in U.S. Manufacturing, Warns of Disruptions 

Bella Czajkowski, National Correspondent 340B Report Views
The drug industry is bracing for the Trump administration’s planned tariffs on pharmaceutical products and ingredients, warning of supply chain [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

RxParadigm

State Contract Pharmacy Lawsuit Roundup: Appellate Court Briefings on 340B Laws in West Virginia, Louisiana

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live